Phase 3 Clinical Trials With Primary Completion Dates in November 2021
This is a list of Phase 3 trials with primary completion dates in November 2021 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|AKBA||Akebia Therapeutics, Inc.||2021-11-01||Phase 3||NCT04313153||Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)|
|ALKS||Alkermes plc||2021-11-01||Phase 3||NCT03187769||Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder|
|ARNA||Arena Pharmaceuticals, Inc.||2021-11-01||Phase 3||NCT03996369||Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis|
|EXEL||Exelixis, Inc.||2021-11-01||Phase 3||NCT03937219||Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma|
|IMGN||ImmunoGen, Inc.||2021-11-01||Phase 3||NCT04296890||A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression|
|NEPH||Nephros, Inc.||2021-11-01||Phase 3||NCT02757872||Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives|
|OPTN||OptiNose, Inc.||2021-11-01||Phase 3||NCT03960580||Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Sinusitis Without the Presence of Nasal Polyps|
|RIGL||Rigel Pharmaceuticals, Inc.||2021-11-01||Phase 3||NCT04629703||Double-Blind, Randomized, Placebo-Controlled, Adaptive Design, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects|
|TEVA||Teva Pharmaceutical Industries Limited||2021-11-01||Phase 3||NCT02688140||Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia|